Literature DB >> 20386436

Role of intermittent hypoxia in the treatment of bronchial asthma and chronic obstructive pulmonary disease.

Myriam Vogtel1, Alexandra Michels.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to describe the impact that exposure to intermittent hypoxic training (IHT) could have on bronchial asthma and chronic obstructive pulmonary disease (COPD). This is of particular interest, as an increasing number of patients suffer from severe symptoms of bronchial asthma and COPD and desire more effective and efficient treatment options with fewer side effects. RECENT
FINDINGS: Exposure to IHT has been shown to raise baroreflex sensitivity to normal levels and to selectively increase hypercapnic ventilatory response, total exercise time, total haemoglobin mass, and lung diffusion capacity for carbon monoxide in COPD patients. However, evidence proving that IHT leads to health benefit effects in bronchial asthma patients has not been produced by recent literature.
SUMMARY: Recent research outlines the value of IHT as a therapeutic strategy for the treatment of COPD patients, leading to more efficient ventilation. Additionally, IHT might represent an attractive method to complement the known beneficial effects of exercise training and to rebalance early autonomic dysfunction in COPD patients. Future research examining the potential risks and benefits of IHT could pave the way for the development of new therapeutic approaches for patients suffering from bronchial asthma and COPD.

Entities:  

Mesh:

Year:  2010        PMID: 20386436     DOI: 10.1097/ACI.0b013e32833903a6

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  8 in total

1.  Intermittent hypoxia mobilizes hematopoietic progenitors and augments cellular and humoral elements of innate immunity in adult men.

Authors:  Tatiana V Serebrovskaya; Igor S Nikolsky; Valentyna V Nikolska; Robert T Mallet; Vadim A Ishchuk
Journal:  High Alt Med Biol       Date:  2011       Impact factor: 1.981

Review 2.  Usefulness of combining intermittent hypoxia and physical exercise in the treatment of obesity.

Authors:  Aritz Urdampilleta; Pedro González-Muniesa; María P Portillo; J Alfredo Martínez
Journal:  J Physiol Biochem       Date:  2011-11-03       Impact factor: 4.158

3.  Oxidative and carbonyl stress in pregnant women with obstructive sleep apnea.

Authors:  Nazia Khan; Geralyn Lambert-Messerlian; Joao Filipe Monteiro; Julius Hodosy; Ľubomíra Tóthová; Peter Celec; Elizabeth Eklund; Patrizia Curran; Ghada Bourjeily
Journal:  Sleep Breath       Date:  2017-02-24       Impact factor: 2.816

4.  Genome-wide association study for atopy and allergic rhinitis in a Singapore Chinese population.

Authors:  Anand Kumar Andiappan; De Yun Wang; Ramani Anantharaman; Pallavi Nilkanth Parate; Bani Kaur Suri; Hui Qi Low; Yi Li; Wanting Zhao; Paola Castagnoli; Jianjun Liu; Fook Tim Chew
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

Review 5.  Impact of hypoxia on male reproductive functions.

Authors:  P A Oyedokun; R E Akhigbe; L O Ajayi; A F Ajayi
Journal:  Mol Cell Biochem       Date:  2022-09-15       Impact factor: 3.842

6.  Intermittent hypoxia treatment alleviates memory impairment in the 6-month-old APPswe/PS1dE9 mice and reduces amyloid beta accumulation and inflammation in the brain.

Authors:  Xiangpei Yue; Yanzhao Zhou; Meng Qiao; Xingnan Zhao; Xin Huang; Tong Zhao; Xiang Cheng; Ming Fan; Yongqi Zhao; Ruoli Chen; Lingling Zhu
Journal:  Alzheimers Res Ther       Date:  2021-11-29       Impact factor: 6.982

Review 7.  Blood biomarkers associated with acute type II respiratory failure in COPD: A meta-analysis.

Authors:  Tieying Shi; Li Feng
Journal:  Clin Respir J       Date:  2022-01-10       Impact factor: 1.761

Review 8.  Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to potential therapeutic targets.

Authors:  Zoya O Serebrovska; Elisa Y Chong; Tetiana V Serebrovska; Lesia V Tumanovska; Lei Xi
Journal:  Acta Pharmacol Sin       Date:  2020-10-27       Impact factor: 7.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.